title: [Hypophosphatemia and tumor-induced osteomalacia].
abstract: In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation. Clinical chemistry results show severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGF-23) is abnormally high. Physiological role of FGF-23 is examined. We also consider the pathophysiology of tumor induced osteomalacia, the use of different investigations to localize the tumor and therapies available to treat this rare disease.
authors.affiliation: Département de médecine nucléaire, CHU Sart-Tilman, Université de Liège, Liège, Belgique. catherinevanderrest@hotmail.com
authors.forename: C
authors.initials: C
authors.lastname: van der Rest
authors.forename: E
authors.initials: E
authors.lastname: Cavalier
authors.forename: L
authors.initials: L
authors.lastname: Colson
authors.forename: J-F
authors.initials: JF
authors.lastname: Kaux
authors.forename: J-M
authors.initials: JM
authors.lastname: Krzesinski
authors.forename: J-Y
authors.initials: JY
authors.lastname: Reginster
authors.forename: R
authors.initials: R
authors.lastname: Hustinx
authors.forename: P
authors.initials: P
authors.lastname: Delanaye
mesh_terms: D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood / Q000502:physiology; D006801:Humans; D017674:Hypophosphatemia / Q000150:complications* / Q000209:etiology / Q000628:therapy; D009369:Neoplasms / Q000150:complications*; D010018:Osteomalacia / Q000209:etiology* / Q000628:therapy
chemical_list: C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23